Data / Research funding / New Jersey / Hackensack University Medical Center
Hackensack University Medical Center: 49 NIH awards ($174.4M), fiscal years 2021 to 2026
Hackensack University Medical Center in Hackensack, NJ is funded under 49 NIH awards ($174.4M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- LV8GL8MLU9A3
- State
- New Jersey
Awards
49 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Metropolitan AntiViral Drug Accelerator | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $65,141,731 | May 16, 2022 | April 30, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $19,798,646 | May 1, 2019 | April 30, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Center for accelerated development of drug candidates targeting high threat bacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $7,562,521 | June 20, 2025 | May 31, 2030 | PERLIN, DAVID S | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| Enriching ECHO Cohorts with High-risk Pregnancies and Children with Disabilities (Enriching ECHO) | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $5,742,893 | September 1, 2023 | May 31, 2025 | ASCHNER, JUDY LYNN | reporter.nih.gov |
| Critical Factors Influencing Echinocandin Resistance in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,673,964 | August 1, 2014 | July 31, 2028 | PERLIN, DAVID S | reporter.nih.gov |
| Enriching ECHO Cohorts with High-risk Pregnancies and Children with Health Challenges (Enriching ECHO) | NIH | Office of the Director, National Institutes of Health | 2025 | $5,019,949 | September 1, 2023 | May 31, 2030 | ASCHNER, JUDY LYNN | reporter.nih.gov |
| Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,578,239 | February 1, 2018 | April 30, 2029 | DICK, THOMAS | reporter.nih.gov |
| TLE transcription cofactors in anti-viral and anti-tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,436,588 | July 18, 2025 | June 30, 2029 | XUE, HAI-HUI | reporter.nih.gov |
| Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge and Uptake in High-Risk Populations | NIH | National Cancer Institute | 2022 to 2025 | $3,421,613 | October 1, 2022 | August 31, 2027 | CARTER-BAWA, LISA | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,053,206 | January 10, 2020 | December 31, 2025 | NAGAJYOTHI, JYOTHI FALGUNI | reporter.nih.gov |
| Translational approaches to improve understanding and outcome in Tuberculous meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,879,850 | March 19, 2020 | March 31, 2026 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| Regulation of T cell exhaustion via 3D chromatin architecture | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,704,065 | March 15, 2015 | April 30, 2030 | XUE, HAI-HUI | reporter.nih.gov |
| Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,534,115 | June 6, 2023 | May 31, 2028 | DICK, THOMAS | reporter.nih.gov |
| Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,524,458 | June 4, 2025 | May 31, 2030 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | NIH | National Cancer Institute | 2022 to 2025 | $2,202,507 | March 1, 2022 | January 31, 2027 | ZAKRZEWSKI, JOHANNES | reporter.nih.gov |
| Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,153,664 | March 22, 2019 | April 30, 2024 | PERLIN, DAVID S | reporter.nih.gov |
| Identifying and characterizing functional noncoding mutations in multiple myeloma | NIH | National Cancer Institute | 2023 to 2025 | $2,150,623 | April 13, 2023 | March 31, 2028 | TYCKO, BENJAMIN | reporter.nih.gov |
| CTCF in CD8 T cell homeostasis and anti-viral/tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,111,431 | June 1, 2016 | July 31, 2027 | XUE, HAI-HUI | reporter.nih.gov |
| DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,948,900 | November 23, 2021 | March 31, 2026 | ZHANG, YI | reporter.nih.gov |
| Celiac and inflammatory bowel diseases: functional post-GWAS approach | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,722,912 | August 19, 2024 | July 31, 2029 | TYCKO, BENJAMIN | reporter.nih.gov |
| Target based discovery of next generation pyrazinamide | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,586,105 | August 1, 2013 | May 31, 2023 | DICK, THOMAS | reporter.nih.gov |
| ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection | NIH | National Cancer Institute | 2024 to 2025 | $1,486,385 | May 1, 2024 | April 30, 2029 | ZHANG, YI | reporter.nih.gov |
| Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,419,468 | September 13, 2022 | May 31, 2027 | LU, BINFENG | reporter.nih.gov |
| Nuclear envelope and predisposition to hepatic neoplasia | NIH | National Cancer Institute | 2023 to 2025 | $1,049,504 | August 1, 2023 | July 31, 2028 | SHIN, JI-YEON | reporter.nih.gov |
| Ezh2 regulates follicular helper T cell differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $957,913 | September 24, 2018 | August 31, 2024 | XUE, HAI-HUI | reporter.nih.gov |
| Rejuvenation of aged hematopoietic stem cells and endothelial niches by thrombospondin-1 blockade | NIH | National Institute on Aging | 2021 to 2022 | $933,748 | September 30, 2019 | July 31, 2022 | BUTLER, JASON MATHEW | reporter.nih.gov |
| Shorter and more effective oral regimens for M. abscessus pulmonary disease | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $895,538 | January 21, 2025 | December 31, 2029 | DICK, THOMAS | reporter.nih.gov |
| Neutrophil extracellular traps and associated pathogenesis in TBI: a novel peptide therapeutic strategy. | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $885,500 | March 6, 2024 | June 19, 2025 | MUNEER, MOHAMMED ABDUL | reporter.nih.gov |
| Dissecting the host-plasmid interplay to unravel the spread of ESBL-producing K. pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $874,998 | August 13, 2025 | June 30, 2030 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Tissue specific immunity to fungal infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $857,215 | November 22, 2024 | October 31, 2029 | CHAUHAN, NEERAJ | reporter.nih.gov |
| Epigenetics of Down Syndrome | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $751,594 | September 13, 2017 | June 30, 2024 | TYCKO, BENJAMIN | reporter.nih.gov |
| Leveraging behavioral science to improve patient understanding of advanced cancer | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | September 1, 2019 | November 30, 2025 | DERRY-VICK, HEATHER | reporter.nih.gov |
| Elucidating the Role of SMAD4 in Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | July 1, 2022 | June 30, 2026 | TONG, KEVIN | reporter.nih.gov |
| Experimental evolution of pancreatic cancer | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | September 9, 2019 | July 31, 2026 | MAKOHON-MOORE, ALVIN | reporter.nih.gov |
| Study of Interleukin 33 as a new immunotherapy of lung cancer | NIH | National Cancer Institute | 2022 to 2023 | $700,410 | July 1, 2019 | August 31, 2025 | LU, BINFENG | reporter.nih.gov |
| The molecular basis of the carbapenem resistance epidemic | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $667,413 | August 1, 2019 | November 30, 2022 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Elucidating mediators of genetic instability in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $510,675 | November 9, 2022 | October 31, 2025 | SHOR, ERIKA | reporter.nih.gov |
| C5a/C5ar1 signaling in protective immunity during invasive candidiasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $498,000 | September 1, 2019 | June 30, 2025 | DESAI, JIGARKUMAR V | reporter.nih.gov |
| Identifying drug-resistant Candida species using SuperSelective primer PCR | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $473,591 | November 25, 2022 | October 31, 2025 | CHAUHAN, NEERAJ | reporter.nih.gov |
| Peptide therapy for alcohol-induced CNS injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $464,887 | May 1, 2023 | April 30, 2025 | MUNEER, MOHAMMED ABDUL | reporter.nih.gov |
| Targeting Transcriptional Co-repressor CoREST Complex in Melanoma | NIH | National Cancer Institute | 2021 | $398,711 | September 1, 2017 | August 31, 2024 | RYU, BYUNGWOO | reporter.nih.gov |
| Cancer Misinformation and Use of Complementary and Alternative Therapy (CAM) among Patients with Cancer. | NIH | National Cancer Institute | 2024 to 2025 | $388,800 | July 1, 2024 | June 30, 2027 | FRIDMAN, ILONA | reporter.nih.gov |
| Optimizing adherence to lung cancer screening: Applying theory and implementation science to participant engagement | NIH | National Cancer Institute | 2023 to 2025 | $304,873 | September 1, 2021 | August 31, 2027 | HIRSCH, ERIN | reporter.nih.gov |
| C25-modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $265,650 | November 13, 2024 | October 31, 2026 | GANAPATHY, UDAY | reporter.nih.gov |
| Effects of antifungal drug treatment and immune dysfunction on the evolutionary dynamics of gut-colonizing Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $265,650 | February 1, 2025 | January 31, 2027 | SHOR, ERIKA | reporter.nih.gov |
| Using a Mixed Methods Approach to Understand Shared Decision-Making in Lung Cancer Screening | NIH | National Cancer Institute | 2022 | $219,125 | October 8, 2022 | August 31, 2025 | CARTER-BAWA, LISA | reporter.nih.gov |
| Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs) | NIH | National Institute of Dental & Craniofacial Research | 2023 | $178,670 | June 1, 2024 | May 31, 2025 | DALERBA, PIERO D | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 25 | $32,541,792 | 0 | $0 |
| 2024 | 26 | $17,019,536 | 0 | $0 |
| 2023 | 26 | $21,025,858 | 0 | $0 |
| 2022 | 25 | $85,592,610 | 0 | $0 |
| 2021 | 16 | $18,265,972 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 27 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 27 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 27 awards here |
Topics of its NIH awards
- Genetics
- Infectious Diseases
- Biotechnology
- Cancer
- Rare Diseases
- Emerging Infectious Diseases
- Antimicrobial Resistance
- Lung
- Orphan Drug
- Prevention
- Translational Research
- Biodefense and Related Countermeasures
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.